Effect of actinomycin D-containing lipid vesicles on murine renal adenocarcinoma.
Forty Balb C/CR mice inoculated with renal cell adenocarcinoma were divided into five groups. Group A (seven animals) received phosphate buffered saline intraperitoneally; group B (seven animals) received free actinomycin D 300 microgram/kg IP; group C (nine animals) received lipid vesicles containing actinomycin D 300 microgram/kg IP; group D (eight animals) received a mixture of free actinomycin D 300 microgram/kg and empty lipid vesicles IP. The median survival of group A was 32 days, of group B 30 days, of group C 45.2 days, of group D 54 days, and of group E 42 days. It is suggested that giving the mixture of the drug and the lipid vesicles produces a balance similar to that found in a vesicle solution containing the actinomycin D. It is also suggested that liposomes slow the absorption of actinomycin D from the peritoneum.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D003609:Dactinomycin / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008081:Liposomes / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000556:secondary; D051379:Mice; D008807:Mice, Inbred BALB C
D008081:Liposomes; D003609:Dactinomycin